Salivary Apelin, Chemerin, Ghrelin, and Lipocalin-2 Levels in Diabetic Patients With Periodontitis

Sponsor
Necmettin Erbakan University
Study ID
NCT07703345
Status
Recruiting
Apply to this trial

Conditions

  • Periodontitis
  • Type 2 Diabetes Mellitus (T2DM)

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • Salivary Biomarker Analysis — DIAGNOSTIC_TEST
    Unstimulated saliva samples will be collected from participants before periodontal treatment and before periodontal probing. Salivary apelin, chemerin, ghrelin, and lipocalin-2 levels will be measured using enzyme-linked immunosorbent assay kits according to the manufacturer's instructions. This procedure is used for biomarker assessment only and does not involve any therapeutic intervention.

Study Details

This observational cross-sectional study will evaluate salivary apelin, chemerin, ghrelin, and lipocalin-2 levels in individuals with different periodontal and systemic conditions. Participants will be divided into four groups according to periodontal status and the presence or absence of type 2 diabetes mellitus. Clinical periodontal measurements and unstimulated saliva samples will be obtained before periodontal treatment. Salivary biomarker levels will be measured using enzyme-linked immunosorbent assay kits. The study aims to determine whether salivary apelin, chemerin, ghrelin, and lipocalin-2 levels are associated with periodontitis, type 2 diabetes mellitus, and periodontal clinical parameters.

Key Dates

First listed
Jul 14, 2026
Start date
Jul 1, 2026
Status verified
Jul 2026
Primary completion
Aug 1, 2026
Completion
Aug 1, 2026

Study Design

Enrollment
88 participants (estimated)

Arms

  • Arm: Periodontally Healthy Systemically Healthy Group
    Periodontally healthy individuals without type 2 diabetes mellitus or other systemic diseases.
  • Arm: Periodontally Healthy Type 2 Diabetes Group
    Periodontally healthy individuals diagnosed with type 2 diabetes mellitus.
  • Arm: Periodontitis Systemically Healthy Group
    Systemically healthy individuals diagnosed with generalized Stage II or Stage III periodontitis according to the 2017 World Workshop Classification.
  • Arm: Periodontitis Type 2 Diabetes Group
    Individuals diagnosed with both generalized Stage II or Stage III periodontitis and type 2 diabetes mellitus.

Primary Outcome Measure

Salivary apelin, chemerin, ghrelin, and lipocalin-2 levels [ Time Frame: Baseline, before periodontal treatment ]

Central Contacts

Related Studies